ACT Genomics has partnered with LSI Medience, a subsidiary of PHC Holdings, to explore collaboration opportunities on genomic and clinical testing services tailored to the Japanese healthcare sector.
The partnership seeks to integrate genomic profiling into clinical research practices, providing personalized information to Japanese researchers. By utilizing ACT Genomics' expertise in genomic profiling technologies and LSI Medience's robust clinical testing services, it aims to accelerate technological innovation in the field. Once determined, specific initiatives and projects pertaining to the collaborative efforts will be announced in the future.
Headquartered in Taiwan, ACT Genomics is a global oncology solution provider specializing in precision oncology through next-generation sequencing (NGS) technology. The company offers a range of genomic profiling services that aid in cancer treatment planning, immunotherapy evaluation, and cancer relapse and drug resistance monitoring. Its flagship product, ACTOnco+, is a comprehensive genomic profiling test for solid tumors, which received FDA clearance in January 2023, the first Asian company to achieve this milestone.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.